{"anticipatedPostingDate":"2027-06","denomUnitsSelected":"Participants","description":"CBR is defined as percentage of participants with a confirmed minimal response (MR) or better per International Myeloma Working Group (IMWG).","reportingStatus":"NOT_POSTED","timeFrame":"Up to 255 weeks","title":"Clinical Benefit Rate (CBR)","type":"SECONDARY"}